Dr Reddy's Laboratories EBIT Margin 2010-2023 | RDY
Current and historical EBIT (Earnings Before Interest & Taxes) margin for Dr Reddy's Laboratories (RDY) over the last 10 years. The current EBIT profit margin for Dr Reddy's Laboratories as of December 31, 2023 is .
| Dr Reddy's Laboratories EBIT Margin Historical Data |
| Date |
TTM Revenue |
TTM EBIT |
EBIT Margin |
| 2023-12-31 |
$3.23B |
$0.78B |
24.00% |
| 2023-09-30 |
$3.19B |
$0.77B |
24.08% |
| 2023-06-30 |
$3.15B |
$0.76B |
23.98% |
| 2023-03-31 |
$2.99B |
$0.70B |
23.23% |
| 2022-12-31 |
$2.95B |
$0.57B |
19.25% |
| 2022-09-30 |
$2.83B |
$0.49B |
17.36% |
| 2022-06-30 |
$2.82B |
$0.45B |
16.08% |
| 2022-03-31 |
$2.83B |
$0.39B |
13.80% |
| 2021-12-31 |
$2.83B |
$0.49B |
17.15% |
| 2021-09-30 |
$2.79B |
$0.47B |
16.93% |
| 2021-06-30 |
$2.67B |
$0.43B |
16.14% |
| 2021-03-31 |
$2.59B |
$0.45B |
17.31% |
| 2020-12-31 |
$2.38B |
$0.46B |
19.13% |
| 2020-09-30 |
$2.32B |
$0.45B |
19.21% |
| 2020-06-30 |
$2.34B |
$0.43B |
18.22% |
| 2020-03-31 |
$2.32B |
$0.44B |
18.78% |
| 2019-12-31 |
$2.46B |
$0.41B |
16.45% |
| 2019-09-30 |
$2.38B |
$0.38B |
16.06% |
| 2019-06-30 |
$2.24B |
$0.35B |
15.63% |
| 2019-03-31 |
$2.23B |
$0.30B |
13.57% |
| 2018-12-31 |
$2.15B |
$0.26B |
12.12% |
| 2018-09-30 |
$2.20B |
$0.26B |
11.72% |
| 2018-06-30 |
$2.21B |
$0.25B |
11.08% |
| 2018-03-31 |
$2.18B |
$0.18B |
8.39% |
| 2017-12-31 |
$2.26B |
$0.20B |
8.75% |
| 2017-09-30 |
$2.22B |
$0.21B |
9.23% |
| 2017-06-30 |
$2.21B |
$0.20B |
8.93% |
| 2017-03-31 |
$2.17B |
$0.21B |
9.58% |
| 2016-12-31 |
$2.09B |
$0.22B |
10.57% |
| 2016-09-30 |
$2.15B |
$0.25B |
11.69% |
| 2016-06-30 |
$2.22B |
$0.34B |
15.43% |
| 2016-03-31 |
$2.34B |
$0.45B |
19.14% |
| 2015-12-31 |
$2.43B |
$0.51B |
21.04% |
| 2015-09-30 |
$2.44B |
$0.51B |
20.98% |
| 2015-06-30 |
$2.40B |
$0.46B |
19.03% |
| 2015-03-31 |
$2.40B |
$0.44B |
18.36% |
| 2014-12-31 |
$2.36B |
$0.40B |
16.82% |
| 2014-09-30 |
$2.32B |
$0.41B |
17.70% |
| 2014-06-30 |
$2.27B |
$0.44B |
19.31% |
| 2014-03-31 |
$2.17B |
$0.40B |
18.37% |
| 2013-12-31 |
$2.20B |
$0.41B |
18.64% |
| 2013-09-30 |
$2.15B |
$0.36B |
16.56% |
| 2013-06-30 |
$2.16B |
$0.35B |
16.27% |
| 2013-03-31 |
$2.14B |
$0.36B |
16.76% |
| 2012-12-31 |
$2.05B |
$0.42B |
20.59% |
| 2012-09-30 |
$2.05B |
$0.49B |
23.86% |
| 2012-06-30 |
$1.96B |
$0.42B |
21.29% |
| 2012-03-31 |
$1.95B |
$0.41B |
21.23% |
| 2011-12-31 |
$1.88B |
$0.29B |
15.42% |
| 2011-09-30 |
$1.78B |
$0.21B |
11.78% |
| 2011-06-30 |
$1.74B |
$0.25B |
14.59% |
| 2011-03-31 |
$1.66B |
$0.24B |
14.52% |
| 2010-12-31 |
$1.57B |
$0.19B |
11.77% |
| 2010-09-30 |
$1.52B |
$0.18B |
11.70% |
| 2010-06-30 |
$1.48B |
$0.15B |
9.78% |
| 2010-03-31 |
$1.50B |
$0.16B |
10.73% |
| 2009-12-31 |
$1.53B |
$0.37B |
23.98% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$11.900B |
$2.992B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
